Early therapy of Parkinson's disease with rasagiline (Azilect) slows down disease progression: results of the study ADAGIO
- Authors: Levin OS1, Levin O1
-
Affiliations:
- Issue: No 5 (2010)
- Pages: 75-80
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/278326
- ID: 278326
Cite item
Full Text
Abstract
Rasagiline (azilect) is next generation inhibitor of monoamine oxidase type B. Its potential to reduce the severity of main parkinsonian symptoms in patients with Parkinson's disease (PD) was previously demonstrated in some controlled trials (TEMPO, PRESTO, LARGO). Design and results of the ADAGIO study - first clinical trial with a delayed start for BP, which confirmed the neuroprotective effect of rasagiline in this disease - are discussed. It is important to emphasize the safety of rasagiline, confirmed in a study ADAGIO: tolerability of rasagiline and placebo was comparable.
References
- Hauser RA, Lew MF, Hurtig HI, et al. Long-term Outcome of Early Versus Delayed Rasagiline Treatment in Early Parkinson's Disease. Movement Disord 2009;24:564-73.
- Olanow CW, Hauser RA, Jankovic J, et al. A randomized, double-blind, placebocontrolled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (The ADAGIO Study): rationale, design, and baseline characteristics. Movement Disord 2008;23:2194-2201.
- Olanow CW, Rascol O, Hauser R, et al. A doubled-blind, delayed-start trial of rasagiline in 4. Parkinson's disease. N Engl J Med 2009;361:1268-78.
- Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002;59:1937-43.
Supplementary files
